Athena Global Technologies Limited reported a standalone net loss of ₹3,969.50 lakh for the financial year ended March 31, 2026, compared to a net loss of ₹1,411.98 lakh in the previous year. The company's revenue from operations for the year stood at ₹805.94 lakh, a decrease from ₹1,217.80 lakh in FY25. The standalone financial results for the fourth quarter and fiscal year were approved by the board on May 30, 2026.

The board also approved the audited consolidated financial results, which showed a net loss of ₹4,567.62 lakh for FY26. The consolidated revenue from operations for the year was ₹1,119.66 lakh, down from ₹1,562.44 lakh in the previous year. The statutory auditors, Ramanatham & Rao, Chartered Accountants, issued an unmodified opinion on both the standalone and consolidated financial results.

Financial Performance

The company's financial performance for the year was significantly impacted by exceptional items. A loss of ₹3,235.60 lakh was recognized due to the sale of investment in subsidiary Medley Medical Solutions Private Limited. Conversely, a gain of ₹2,339.75 lakh was recorded from the derecognition of investment property following a perpetual lease agreement executed in November 2025.

Key Board Decisions

During the meeting held on May 30, 2026, the board approved several key resolutions. M/s. Sarda & Agarwal, Chartered Accountants, were appointed as internal auditors for FY 2026-27. Additionally, the board approved a proposal to invest up to ₹50 crores in Optionally Convertible Debentures (OCDs) of Medley Medical Solutions Private Limited and Tutoroot Technologies Private Limited, in one or more tranches.

The trading window for dealing in equity shares, which was closed since April 01, 2026, will remain closed until 48 hours after the financial results are announced to the public. This restriction applies to all designated persons, their immediate relatives, and connected persons in compliance with SEBI regulations.

Athena Global Technologies Limited has completed the preferential allotment of 7,00,000 share warrants to a promoter group member, marking a significant capital raising initiative for the Hyderabad-based technology company.

Board Approval and Allotment Details

The Board of Directors approved the allotment in their meeting held on April 13, 2026, which commenced at 01:45 PM and concluded at 02:15 PM. The warrants have been allotted to Karthikeya Manchala, a promoter group member, at an issue price of Rs. 84 per warrant.

Regulatory Compliance and Approvals

The allotment follows a structured approval process that ensures full regulatory compliance. The company received shareholder approval through an extraordinary general meeting held on March 25, 2026, followed by in-principle approval from BSE Limited on April 1, 2026.

The transaction has been executed in accordance with:

• SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018
• Companies Act, 2013 provisions
• Terms mentioned in the EGM notice dated March 25, 2026

Financial Structure and Conversion Terms

Under SEBI regulations, the company has received 25% of the total consideration, amounting to Rs. 1,47,00,000. The warrants are convertible into an equal number of fully paid-up equity shares upon receipt of the balance amount within the stipulated timeframe.

As the company has allotted convertible warrants rather than equity shares, there is no immediate change in the paid-up capital of the company. The paid-up capital will increase only upon conversion of the warrants into equity shares.

Corporate Communication

The outcome was communicated to BSE Limited through a formal letter signed by Gayathri Prithviraj, Company Secretary and Compliance Officer. The communication included detailed annexures as required under Regulation 30 of the SEBI Listing Regulations and SEBI Master Circular dated January 30, 2026.